logo
Is Lucid Group Stock a Buy Now?

Is Lucid Group Stock a Buy Now?

Yahoo31-03-2025

Lucid Group (NASDAQ: LCID) is a premium electric vehicle (EV) manufacturer that has captured attention with its innovative automotive offerings. The company has made noteworthy advancements in EV technology, especially with the Lucid Air and the upcoming Lucid Gravity SUV.
Lucid's long-term growth potential in the EV market is promising. The company is making solid progress, and its new SUV could be a game changer. That said, the EV maker has faced significant financial challenges, including the need for ongoing cash infusions from investors. If you're thinking of investing in Lucid, consider the following first.
Lucid Group attracts an affluent customer base with its premium automotive brand. It offers the Lucid Air Pure, which has 430 horsepower and a range of 420 miles per charge. At $69,900, this model is Lucid's more affordable option.
For those seeking higher performance and a more extended driving range, its Grand Touring and Sapphire offer impressive capabilities. However, customers will have to pay up, as these vehicles cost $110,900 and $249,000, respectively.
Lucid's recent fourth-quarter earnings results were decent. The company beat analysts' revenue estimates, posting $234.5 million compared to $211.77 million expected. It also exceeded earnings per share (EPS), posting a $0.22 loss per share vs. the $0.28 loss per share expected. The EV maker has ramped up production and deliveries, which is essential for achieving scale and profitability down the road. It closed the year with 10,241 vehicle deliveries, up 71% from one year ago.
Another offering is Lucid Gravity, Lucid's long-awaited SUV model. The premium SUV is priced at $94,900 and can travel 450 miles on a single charge. It also has fast-charging capabilities, allowing it to travel up to 200 miles after charging for just 12 minutes.
Analysts at TD Cowen believe that the Lucid Gravity vehicle could be "a turning point for the company." However, those analysts also say the price "strikes us as too high" and that Lucid could struggle to generate enough volume.
In other news, Lucid CEO Peter Rawlinson recently stepped down, and Chief Operating Officer Marc Winterhoff was named interim CEO. Bank of America analysts argue that this move is "much more consequential than understood by the market." BofA thinks that product development could stall, and demand may also be impacted as it cut its forecasts for future production volumes.
Lucid's technology is quite impressive. However, getting to this point has been an expensive journey. The company has invested massively in its technology and needs to scale up and sell more volume to achieve positive cash flows. Over the past three years, the company has posted a net loss of $8.5 billion.
This cash situation makes Lucid a risky proposition for investors today. The company has already raised $8.9 billion from the Public Investment Fund of Saudi Arabia. It has also had to tap into equity markets several times. Both moves have severely diluted shareholders.
Since 2021, Lucid's outstanding share count has gone from 1.62 billion to 3.03 billion, and the stock has fallen from its peak of $57.75 per share to $2.41, a staggering 96% decline.
The company has needed a massive upfront investment, and this raises questions about how much more the Public Investment Fund and other equity investors are willing to fund this business. The company has about $6.1 billion in liquidity, giving it enough runway to fund operations into the second half of 2026.
According to a projection from PwC, the number of EVs in the U.S. could grow to 27 million in 2030 and 92 million in 2040. This gives Lucid and other EV makers a vast potential future market opportunity. Competition remains fierce, with Tesla being a massive player and Rivian Automotive emerging as another competitor. Lucid hopes its premium brand allows it to carve out its niche for EV customers willing to pay up.
The current political environment also creates uncertainty about widespread EV adoption. Recently, the Trump administration ordered the federal government to sell 25,000 EV chargers. There is also a concern that the $7,500 EV tax credit and other subsidies could be at risk.
Lucid's technology is impressive, and new offerings could help it achieve profitability -- provided it can increase sales and control costs. However, there are challenges in the near term. Investors should continue to monitor the economic backdrop, along with deliveries, cost management, and Gravity sales. Until Lucid makes notable improvements in its bottom line, investors are better off avoiding this stock for now.
Before you buy stock in Lucid Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $726,481!*
Now, it's worth noting Stock Advisor's total average return is 835% — a market-crushing outperformance compared to 164% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of March 18, 2025
Courtney Carlsen has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy.
Is Lucid Group Stock a Buy Now? was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Yahoo

time31 minutes ago

  • Yahoo

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@

Why Guardant Health Stock Surged Nearly 9% Higher Today
Why Guardant Health Stock Surged Nearly 9% Higher Today

Yahoo

time41 minutes ago

  • Yahoo

Why Guardant Health Stock Surged Nearly 9% Higher Today

The company's Shield multi-cancer detection test won an important designation from a top regulator. This should help bring it to market quicker. 10 stocks we like better than Guardant Health › Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%. This morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cancer detection (MCD) test its Breakthrough Device designation. This instantly confers a high status on Shield, as the FDA's designation is given only to a small clutch of medical devices that can either diagnose or treat a disease more effectively than other products. In Shield's case, it is quite a versatile diagnostic device that can screen for a wide range of cancers, including colorectal, lung, and ovarian. It is designed to evaluate people 45 years of age or older who are at a typical average risk for cancer. According to Guardant, Shield has 98.6% specificity and 75% sensitivity in detecting certain cancers. In its news release touting the FDA's move, Guardant quoted its co-CEO AmirAli Talasaz as saying that it "shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw." "We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly," he added. Another big plus of the Breakthrough Device designation is that it's part of an FDA initiative aimed at getting useful medical products to market faster. Talasaz and his team at Guardant might just get their wish with Shield before long. Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy. Why Guardant Health Stock Surged Nearly 9% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Fundhost Selects SS&C to Power Fund Accounting & Registry Services
Fundhost Selects SS&C to Power Fund Accounting & Registry Services

Yahoo

timean hour ago

  • Yahoo

Fundhost Selects SS&C to Power Fund Accounting & Registry Services

WINDSOR, Conn., June 03, 2025--(BUSINESS WIRE)--SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced Fundhost Limited, a boutique fund services provider to investment managers in Australia, has selected SS&C to support its fund services operations. Fundhost provides responsible entity, trustee, fund administration, registry, compliance, operations and support services to boutique Australian and international fund managers. The platform has AUD $2 billion in assets under management. Under the agreement, Fundhost will use SS&C's proprietary platform to streamline its unit registry and fund administration operations. As part of the transition, 10 Fundhost employees have joined SS&C's Sydney office to ensure continuity of service and a seamless onboarding process for Fundhost clients. "We are delighted to partner with SS&C Technologies, a global leader in fund administration and registry services," said Anne Monge, Fundhost founder and Joint-CEO. Drew Wilson, Joint-CEO of Fundhost, added: "We selected SS&C for their proven expertise across private markets, hedge funds, and active ETFs, as well as their global infrastructure. With access to SS&C's technology and operational resources, we're well-positioned to broaden our capabilities while maintaining the high level of service our clients rely on." The agreement expands SS&C's presence in Australia and reinforces its commitment to supporting the local investment management industry with flexible, scalable solutions. "We're excited to welcome our new colleagues and to deepen our presence in the Australian market," said Euan McLeod, Head of Transfer Agency, SS&C Global Investor & Distribution Solutions, Australia. "As demand for business process outsourcing continues to accelerate, we remain committed to delivering market-leading services to fund managers, custodians, and responsible entities across Australia." About Fundhost Fundhost is a leading integrated Responsible Entity offering responsible entity, trustee, accounting, administration, registry and via strategic relationship with HSBC, custody under one roof. A boutique itself, Fundhost has supported the development of some of Australia's most successful boutiques. About SS&C SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at Follow SS&C on X, LinkedIn and Facebook. View source version on Contacts Brian SchellChief Financial OfficerSS&C TechnologiesTel: +1-816-642-0915Email: InvestorRelations@ Justine StoneInvestor RelationsSS&C TechnologiesTel: +1- 212-367-4705Email: InvestorRelations@ Drew WilsonJoint-CEOFundhost LimitedTel: +61 414 755 954Email: dreww@ Media Contacts Sam Gentile | ProsekTel: +1-646-818-9195Email: pro-SSC@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store